Belite Bio’s Post

📣NEW: Rezolute receives Innovative Passport Designation from the U.K. Innovative Licensing and Access Pathway (ILAP) for their hyperinsulinism drug RZ358. This designation is a first step to accelerating the drug to market. For more information on this exciting development, visit https://bit.ly/4984gV2 💙🩵 #hyperinsulinism #raredisease #congenitalhyperinsulinism #hypoglycemia | Hyperinsulinism | Congenital | HI | Hypoglycemia | Rare Disease

#Rarediseaseday2024 #rarediseaseawareness #29thFeb2024 👉 #Rarediseaseday is observed on the last day of February and hence, this year, it will be observed on Thursday, February 29, a rare date, symbolizing the rarity and uniqueness of these conditions. It has grown into a global movement, with participation from over 100 countries worldwide since 2008 ☘ According to newest statistics, there are 300 millions people worldwide living with a rare disease. Even though these diseases might be rare, they still have a big impact on the lives of those who have them and their families. The day advocates for better healthcare facilities for rare diseases. It's also a chance for everyone to come together, show kindness, and make a difference in the lives of those who need it most. ⚕ As a pharmaceutical manufacturer and a supplier, #Vinphaco understands the importance of providing quality and affordable drugs that will help patients receive the most sufficient treatment. We will act together to build a better world 🙏.

The significance of Regulatory CMC is magnified in the context of Orphan Drug Status due to the urgent need for therapies in rare disease populations. These patients frequently have limited or no treatment options, underscoring the necessity for rapid development and approval of new drugs. The FDA's focused efforts to address this need are evident, with over half of the Center for Drug Evaluation and Research's (CDER) novel drug approvals in 2023 targeting rare diseases. This emphasis highlights the critical role of Regulatory CMC in ensuring the quality, safety, and efficacy of these urgently needed treatments but also underscores the importance of streamlined and efficient regulatory pathways to bring these therapies to patients swiftly. The detailed outcomes and impact of these approvals on rare disease treatment landscapes can be further explored in the specified sections of the recent FDA report, providing valuable insights into the advancements in this vital area of drug development. FDA Enkrisi #FDA #CMC

The CARE Plan pilot will promote research and development of new rare disease drugs to address urgent unmet clinical needs in China, and offers the opportunity to involve Chinese patients in rare disease product development. It’s a valuable opportunity for local and foreign companies to have increased interactions with and input from the CDE during the development of their rare disease drugs. Find out more from my colleague Mingping Zhang, in our latest Regulatory Navigator blog.

The CARE Plan pilot will promote research and development of new rare disease drugs to address urgent unmet clinical needs in China, and offers the opportunity to involve Chinese patients in rare disease product development. It’s a valuable opportunity for local and foreign companies to have increased interactions with and input from the CDE during the development of their rare disease drugs. Find out more from my colleague Mingping Zhang, in our latest Regulatory Navigator blog.

The CARE Plan pilot will promote research and development of new rare disease drugs to address urgent unmet clinical needs in China, and offers the opportunity to involve Chinese patients in rare disease product development. It’s a valuable opportunity for local and foreign companies to have increased interactions with and input from the CDE during the development of their rare disease drugs. Find out more from my colleague Mingping Zhang, in our latest Regulatory Navigator blog.

The CARE Plan pilot will promote research and development of new rare disease drugs to address urgent unmet clinical needs in China, and offers the opportunity to involve Chinese patients in rare disease product development. It’s a valuable opportunity for local and foreign companies to have increased interactions with and input from the CDE during the development of their rare disease drugs. Find out more from my colleague Mingping Zhang, in our latest Regulatory Navigator blog.

Ivermectin is a new type of broad-spectrum, high-efficiency, low-toxic semi-synthetic antibiotic antiparasitic drug, which has a good killing effect on internal and external parasites, especially nematodes and arthropods. #Praziquantel #ChemicalAPI #Antiparasitic #parasiticinfection #medicalinsurance #chemistrymedicine

The rarest day of the year! #rarediseaseday2024 Orphan diseases are rare – yet, when their numbers are combined, we see that one in 12 persons in the world is a sufferer. That is a big job for pharmaceutical companies to take on. In this video, we explore the challenges and the available support – and mark World Rare Disease Day. With Ellinor Lindholm and Lovisa Rosenquist. #raredisease #rarediseaseday #arexadvisor #regulatoryaffairs